相关实验视频

Updated: Jun 18, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

对NSCLC患者手术复杂性和短期预后指标的分析:新辅助向治疗与新辅助化学免疫疗法对比

Kun Wang¹, Hang Yi¹, Zhuoheng Lv¹

¹Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Therapeutic advances in medical oncology

|August 2, 2024

概括

与新辅助化学免疫疗法 (NCI) 相比,新辅助向治疗 (NTT) 导致非小细胞肺癌患者的手术更简单,结果更好. 这两种治疗都提供了类似的病理反应率,但对于具有特定突变的患者来说,NTT是首选的.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
新辅助疗法是一种新辅助疗法.

背景情况:

新辅助疗法提高了局部发达的非小细胞肺癌 (NSCLC) 的存活率.
然而,新辅助疗法增加了组织密度,使手术过程复杂化.
这对进行肺癌切除的外科医生来说是一个关键的挑战.

研究的目的:

为了比较新辅助向治疗 (NTT) 和新辅助化学免疫治疗 (NCI) 之间的手术复杂性和短期结果.
评估不同新辅助疗法对外科手术和患者康复的影响.
分析NTT与NCI之后的病理指标.

主要方法:

一项对106名本地发达NSCLC患者的回顾性研究,这些患者在新辅助疗法后接受了治疗性手术.
患者被分为两个组:NTT (33名患者) 和NCI (73名患者).
组间进行了手术复杂性,短期结果和病理反应率的比较.

主要成果:

NTT组显示较高的微创手术率 (84.8%对53.4%),较短的手术时间 (144对184分钟) 和较低的转化率 (3.3%对17.8%).
手术后的结果有利于NTT,排水量较少,心律失常等并发症较少 (6.1%对26%).
病理反应率相似 (70%的NTT与75%的NCI),主要或淋巴结反应没有显著差异.

结论:

与新辅助化学免疫疗法 (NCI) 相比,新辅助向治疗 (NTT) 导致手术复杂性降低和手术结果改善.
在NTT和NCI之间,病理反应率相似.
对于具有特定突变状态的患者,推NTT作为首选的新辅助疗法.

关键词:

辅助疗法是一种辅助疗法.免疫治疗结果的结果非小细胞肺癌的肺癌.研究结果研究成果.有针对性的治疗.

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...